Rowena Henderson

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Ruth M. de Tute, Charlotte Pawlyn, David A. Cairns et al. · Journal of Clinical Oncology · 2022 · 85 citations · Full text

Medicine, Oncology, Immunotherapy +14

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

John R Jones, David A. Cairns, Walter M. Gregory et al. · Blood Cancer Journal · 2016 · 77 citations · Full text

Medicine, Hematology, Oncology +11

<i>F</i> railty-adjusted therapy <i>i</i> n <i>T</i> ransplant <i>N</i> on- <i>E</i> ligible patient <i>s</i> with newly diagno <i>s</i> ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

Amy Beth Coulson, Kara‐Louise Royle, Charlotte Pawlyn et al. · BMJ Open · 2022 · 33 citations · Full text

Medicine, Geriatric Medicine, Oncology +12

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Charlotte Pawlyn, Tom Menzies, Faith E. Davies et al. · Blood · 2022 · 24 citations

Medicine, Hematology, Oncology +17

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M. de Tute, David A. Cairns, Andy C. Rawstron et al. · Blood · 2017 · 13 citations

Medicine, Hematology, Oncology +16